Support for Growth-Phase Biotech Companies
Benefits to an Early Start
Pricing strategy
A more thoughtful and considered pricing approach
Health-economic potential
Maximization of health-economic potential of Phase II / III clinical data
Efficacy-price relationship
A better understanding of your new treatment's efficacy-price relationship, for maximized cost-effectiveness
Influential cost-effectiveness parameters
Understanding those parameters and identifying the need for additional data collection to support chosen parameter values
Saving time
By addressing data gaps early on and transitioning quickly from early to final CE model
Robustness
More robust cost-effectiveness results
How We Help Emerging Companies Succeed
HEOR Support
The growth phase is the best time to optimize resources.
Cost-effectiveness considerations do not have to wait until Phase III, and are in fact integral from the early stages.
Companies taking their first steps towards ground-breaking medical advancements greatly benefit from an early review of their study protocols, and an initial economic assessment of their treatment. ​​
​
They will be all the more prepared when they eventually submit their economic analysis to the health-technology assessment authorities.
Our Early Model
At SHE, we support growth-stage biotech companies without an HEOR department, including through:​​
-
Review and advice on HEOR endpoints in Phase III study protocols
-
Development of an Early Economic Model
-
Advice and proposal of further data collection/analysis to prepare for HTA economic model
-
Strategic advice on commercial assessment and external environment mapping